Primary Care
Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study)
BMJ 2004; 328 doi: https://doi.org/10.1136/bmj.37970.629537.0D (Published 26 February 2004) Cite this as: BMJ 2004;328:495
Data supplement
- Posted as supplied by authors
Table A (detailed according to normotensives / hypertensives): Baseline characteristics of the 4,912 randomised type 2 diabetes patients according to treatment group.
Normotensives (n = 2177)
Hypertensives (n = 2735)
Ramipril (n = 1065)
Placebo (n = 1112)
Ramipril (n = 1378)
Placebo (n = 1357)
Sex (M/F) 797 / 268 840 / 272 904 / 474 891 / 466 Age (years) 63.8 ( 8.6) 63.8 (8.1) 66.2 (8.2) 65.9 (8.3) BMI* (kg/m2) 28.5 (4.3) 28.4 (4.5) 29.6 ( 4.6) 29.8 (4.7) Fasting blood glucose (mmol/L) 9.8 (3.1) 9.9 (3.2) 9.5 (3.1) 9.7 (3.3) HbA1c (%) 7.90 (1.87) 7.76 (1.84) 7.79 (1.80) 7.80 (1.81) Diabetes duration (years) 9.3 (7.4) 9.5 (7.5) 10.1 (7.2) 10.0 (7.4) Systolic blood pressure (mmHg) 139.7 (13.1) 139.4 (12.9) 151.6 (17.1) 151.5 (17.1) Diastolic blood pressure (mmHg) 80.1 (7.9) 80.0 (7.7) 85.0 (9.4) 84.9 (9.9) Smoker (³ 1 cigarette/day)
194 (18.2) 200 (18.0) 177 (12.8) 185 (13.6) Alcohol consumption (³ 1 glass/day)
511 (48.0) 509 (45.6) 612 (44.4) 626 (46.1) Serum creatinine (µmol/L) 86.2 (18.2) 87.4 (18.2) 91.6 (22.2) 90.7 (20.6)
Posted as supplied by authors
Table A (detailed according to normotensives / hypertensives): Baseline characteristics of the 4,912 randomised type 2 diabetes patients according to treatment group.
Normotensives
(n = 2177)Hypertensives
(n = 2735)Ramipril (n = 1065)
Placebo (n = 1112)
Ramipril (n = 1378)
Placebo (n = 1357)
Sex (M/F) 797 / 268 840 / 272 904 / 474 891 / 466 Age (years) 63.8 ( 8.6) 63.8 (8.1) 66.2 (8.2) 65.9 (8.3) BMI* (kg/m2) 28.5 (4.3) 28.4 (4.5) 29.6 ( 4.6) 29.8 (4.7) Fasting blood glucose (mmol/L) 9.8 (3.1) 9.9 (3.2) 9.5 (3.1) 9.7 (3.3) HbA1c (%) 7.90 (1.87) 7.76 (1.84) 7.79 (1.80) 7.80 (1.81) Diabetes duration (years) 9.3 (7.4) 9.5 (7.5) 10.1 (7.2) 10.0 (7.4) Systolic blood pressure (mmHg) 139.7 (13.1) 139.4 (12.9) 151.6 (17.1) 151.5 (17.1) Diastolic blood pressure (mmHg) 80.1 (7.9) 80.0 (7.7) 85.0 (9.4) 84.9 (9.9) Smoker (³ 1 cigarette/day)
194 (18.2) 200 (18.0) 177 (12.8) 185 (13.6) Alcohol consumption (³ 1 glass/day)
511 (48.0) 509 (45.6) 612 (44.4) 626 (46.1) Serum creatinine (µmol/L) 86.2 (18.2) 87.4 (18.2) 91.6 (22.2) 90.7 (20.6)
Related articles
- This Week In The BMJ Published: 26 February 2004; BMJ 328 doi:10.1136/bmj.328.7438.0-c
- Editorial Published: 26 February 2004; BMJ 328 doi:10.1136/bmj.328.7438.473
- Correction Published: 18 March 2004; BMJ 328 doi:10.1136/bmj.328.7441.686-b
- Endgames Published: 26 July 2013; BMJ 347 doi:10.1136/bmj.f4663
- Research Published: 03 October 2013; BMJ 347 doi:10.1136/bmj.f5680
- Research Published: 24 October 2013; BMJ 347 doi:10.1136/bmj.f6008
- Letter Published: 22 April 2004; BMJ 328 doi:10.1136/bmj.328.7446.1016-b
- Clinical Review Published: 21 November 2016; BMJ 355 doi:10.1136/bmj.i5719
See more
- Covid-19: UK government must “get its act together” as modelling suggests 85 000 deaths in second wave, experts sayBMJ October 30, 2020, 371 m4242; DOI: https://doi.org/10.1136/bmj.m4242
- Covid-19: a fork in the road ahead for general practice or a knife severing the road behind?BMJ October 30, 2020, 371 m4231; DOI: https://doi.org/10.1136/bmj.m4231
- General practice: BMA reiterates call for extra support as workload mountsBMJ October 30, 2020, 371 m4240; DOI: https://doi.org/10.1136/bmj.m4240
- Protecting health in dry cities: considerations for policy makersBMJ October 30, 2020, 371 m2936; DOI: https://doi.org/10.1136/bmj.m2936
- New Zealanders vote to legalise assisted dying for terminally ill adultsBMJ October 30, 2020, 371 m4239; DOI: https://doi.org/10.1136/bmj.m4239
Cited by...
- Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes
- Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk
- Management of mild hypertension in adults
- Dynamic Changes in Renal Function Are Associated With Major Cardiovascular Events in Patients With Type 2 Diabetes
- Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis
- Plasma Adrenomedullin and Allelic Variation in the ADM Gene and Kidney Disease in People With Type 2 Diabetes
- Randomized Controlled Trials of Blood Pressure Lowering in Hypertension: A Critical Reappraisal
- Plasma Copeptin and Renal Outcomes in Patients With Type 2 Diabetes and Albuminuria
- Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis
- Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials
- Kaplan-Meier survival analysis: types of censored observations
- Metabolomics and ischaemic heart disease
- A Meta-Analysis Reporting Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients Without Heart Failure
- Risk prediction models: II. External validation, model updating, and impact assessment
- Mortality Rates in Trials of Subjects With Type 2 Diabetes
- Low-Frequency Variants in HMGA1 Are Not Associated With Type 2 Diabetes Risk
- Albuminuria and Cardiovascular Risk: Time for a New Direction?
- Impact of Natriuretic Peptide Clearance Receptor (NPR3) Gene Variants on Blood Pressure in Type 2 Diabetes
- Blood Pressure Variability and Risk of New-Onset Atrial Fibrillation: A Systematic Review of Randomized Trials of Antihypertensive Drugs
- Monitoring Initial Response to Angiotensin-Converting Enzyme Inhibitor-Based Regimens: An Individual Patient Data Meta-Analysis From Randomized, Placebo-Controlled Trials
- Prognostic Value of the Insertion/Deletion Polymorphism of the ACE Gene in Type 2 Diabetic Subjects: Results from the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique (SURDIAGENE) studies
- The Common -866G>A Variant in the Promoter of UCP2 Is Associated With Decreased Risk of Coronary Artery Disease in Type 2 Diabetic Men
- Diabetes, the Metabolic Syndrome, and Ischemic Stroke: Epidemiology and possible mechanisms
- The CETP TaqIB Polymorphism Is Associated With the Risk of Sudden Death in Type 2 Diabetic Patients
- Brachial Pressure-Independent Reduction in Carotid Stiffness After Long-Term Angiotensin-Converting Enzyme Inhibition in Diabetic Hypertensives
- Assessment of Patients'' and Physicians'' Compliance to an ACE Inhibitor Treatment Based on Urinary N-Acetyl Ser-Asp-Lys-Pro Determination in the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) Study.
- Other articles noted
- Confidence intervals illuminate absence of evidence
- Does Low-Dose Ramipril Offer Cardiovascular and Renal Protection?
- Low-Dose Ramipril Doesn't Prevent Cardiovascular Problems in Type 2 Diabetes
- Integrating Drug Pharmacokinetics for Phenotyping Individual Renin Response to Angiotensin II Blockade in Humans
- What doesn't work and how to show it